The cost for PROLARIS is $3,400.

In the United States, 192,000 men are diagnosed with prostate cancer each year and 80,000 men will undergo a radical prostatectomy, a surgical procedure that removes the prostate gland and some surrounding tissue. Approximately 35% of these men will eventually have a biochemical recurrence indicating the return of their prostate cancer. Current models based on clinical variables cannot effectively predict in which of these men the disease will recur.

PROLARIS is a molecular diagnostic assay that offers urologists a more accurate way of determining a prostate cancer patient's risk of recurrence. The new molecular diagnostic test is based on cell growth and tumor biology and provides rigorous دقيق, quantitative measures of the expression levels of multiple genes related to progression of the cell cycle.